Cargando…
Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea
Abdominal pain is the principal symptom of irritable bowel syndrome (IBS). This analysis examined abdominal pain response in adults with IBS with diarrhea (IBS-D) receiving the nonsystemic antibiotic rifaximin. METHODS: In the Targeted Nonsystemic Antibiotic Rifaximin Gut-Selective Evaluation of Tre...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145050/ https://www.ncbi.nlm.nih.gov/pubmed/32352714 http://dx.doi.org/10.14309/ctg.0000000000000144 |
_version_ | 1783519935064965120 |
---|---|
author | Lembo, Anthony Rao, Satish S. C. Heimanson, Zeev Pimentel, Mark |
author_facet | Lembo, Anthony Rao, Satish S. C. Heimanson, Zeev Pimentel, Mark |
author_sort | Lembo, Anthony |
collection | PubMed |
description | Abdominal pain is the principal symptom of irritable bowel syndrome (IBS). This analysis examined abdominal pain response in adults with IBS with diarrhea (IBS-D) receiving the nonsystemic antibiotic rifaximin. METHODS: In the Targeted Nonsystemic Antibiotic Rifaximin Gut-Selective Evaluation of Treatment for IBS-D 3 trial, adults with IBS-D received open-label rifaximin 550 mg 3 times daily for 2 weeks, followed by the 4-week post-treatment phase assessing abdominal pain and stool consistency response. Responders were followed for up to 18 additional weeks; patients with recurrence were randomly assigned to receive two 2-week courses of double-blind rifaximin 550 mg 3 times daily or placebo, separated by 10 weeks. Analyses evaluated mean weekly improvements from baseline (e.g., ≥30%, ≥40%, and ≥50%) in abdominal pain during the 4-week post–repeat-treatment phases. RESULTS: Of the 2,438 evaluable patients, 1,384 (56.8%) had abdominal pain response to open-label rifaximin (≥30% improvement from baseline in the mean weekly abdominal pain score during ≥2 of the first 4 weeks post-treatment). Weekly decrease (improvement) in responders' mean abdominal pain score (scale range, 0–10) from baseline ranged from −2.6 to −3.3 points during the 18-week follow-up. After the first double-blind repeat treatment, a significantly higher percentage of rifaximin-treated patients were abdominal pain responders (53.9% [172/319]) vs placebo (44.4% [134/302], P = 0.02), with similar results after the second repeat treatment (52.9% [155/293] vs 44.7% [123/275], respectively, P = 0.047). A significantly higher percentage of rifaximin-treated patients were weekly abdominal pain responders for ≥50% of the 18-week double-blind repeat treatment phase (47.9% [138/288] vs 35.9% [97/270], P = 0.004). DISCUSSION: Rifaximin is efficacious in improving abdominal pain in adults with IBS-D. |
format | Online Article Text |
id | pubmed-7145050 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Wolters Kluwer |
record_format | MEDLINE/PubMed |
spelling | pubmed-71450502020-04-17 Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea Lembo, Anthony Rao, Satish S. C. Heimanson, Zeev Pimentel, Mark Clin Transl Gastroenterol Article Abdominal pain is the principal symptom of irritable bowel syndrome (IBS). This analysis examined abdominal pain response in adults with IBS with diarrhea (IBS-D) receiving the nonsystemic antibiotic rifaximin. METHODS: In the Targeted Nonsystemic Antibiotic Rifaximin Gut-Selective Evaluation of Treatment for IBS-D 3 trial, adults with IBS-D received open-label rifaximin 550 mg 3 times daily for 2 weeks, followed by the 4-week post-treatment phase assessing abdominal pain and stool consistency response. Responders were followed for up to 18 additional weeks; patients with recurrence were randomly assigned to receive two 2-week courses of double-blind rifaximin 550 mg 3 times daily or placebo, separated by 10 weeks. Analyses evaluated mean weekly improvements from baseline (e.g., ≥30%, ≥40%, and ≥50%) in abdominal pain during the 4-week post–repeat-treatment phases. RESULTS: Of the 2,438 evaluable patients, 1,384 (56.8%) had abdominal pain response to open-label rifaximin (≥30% improvement from baseline in the mean weekly abdominal pain score during ≥2 of the first 4 weeks post-treatment). Weekly decrease (improvement) in responders' mean abdominal pain score (scale range, 0–10) from baseline ranged from −2.6 to −3.3 points during the 18-week follow-up. After the first double-blind repeat treatment, a significantly higher percentage of rifaximin-treated patients were abdominal pain responders (53.9% [172/319]) vs placebo (44.4% [134/302], P = 0.02), with similar results after the second repeat treatment (52.9% [155/293] vs 44.7% [123/275], respectively, P = 0.047). A significantly higher percentage of rifaximin-treated patients were weekly abdominal pain responders for ≥50% of the 18-week double-blind repeat treatment phase (47.9% [138/288] vs 35.9% [97/270], P = 0.004). DISCUSSION: Rifaximin is efficacious in improving abdominal pain in adults with IBS-D. Wolters Kluwer 2020-03-06 /pmc/articles/PMC7145050/ /pubmed/32352714 http://dx.doi.org/10.14309/ctg.0000000000000144 Text en © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Article Lembo, Anthony Rao, Satish S. C. Heimanson, Zeev Pimentel, Mark Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea |
title | Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea |
title_full | Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea |
title_fullStr | Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea |
title_full_unstemmed | Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea |
title_short | Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea |
title_sort | abdominal pain response to rifaximin in patients with irritable bowel syndrome with diarrhea |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145050/ https://www.ncbi.nlm.nih.gov/pubmed/32352714 http://dx.doi.org/10.14309/ctg.0000000000000144 |
work_keys_str_mv | AT lemboanthony abdominalpainresponsetorifaximininpatientswithirritablebowelsyndromewithdiarrhea AT raosatishsc abdominalpainresponsetorifaximininpatientswithirritablebowelsyndromewithdiarrhea AT heimansonzeev abdominalpainresponsetorifaximininpatientswithirritablebowelsyndromewithdiarrhea AT pimentelmark abdominalpainresponsetorifaximininpatientswithirritablebowelsyndromewithdiarrhea |